Figure 8.
Figure 8. PTD-A2 contributes to retinal neovascularization in an OIR model. (A) Scheme and schedule of PTD-A2 treatment in the mouse OIR model. (B and F) Stereomicroscopy and iB4 staining of whole-mount retinas from Con- and TAT-A2– or NGR-Con– and NGR-A2–injected mice (n = 7–8 mice per group; 8 mg/kg of peptide administered every day during P12–P16) with ischemic retinopathy at P17, and quantification of vascular (C and G) and avascular areas (D and H) and the neovascular tufts (E and I). (B and F) Top images are whole-mount retinas and indicate retinal hemorrhage. The bottom images are iB4-staining of flat-mount retinas and indicate the avascular area and neovascular tuft formation. Bars, 200 µm. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ns, not significant. Data are means ± SD.

PTD-A2 contributes to retinal neovascularization in an OIR model. (A) Scheme and schedule of PTD-A2 treatment in the mouse OIR model. (B and F) Stereomicroscopy and iB4 staining of whole-mount retinas from Con- and TAT-A2– or NGR-Con– and NGR-A2–injected mice (n = 7–8 mice per group; 8 mg/kg of peptide administered every day during P12–P16) with ischemic retinopathy at P17, and quantification of vascular (C and G) and avascular areas (D and H) and the neovascular tufts (E and I). (B and F) Top images are whole-mount retinas and indicate retinal hemorrhage. The bottom images are iB4-staining of flat-mount retinas and indicate the avascular area and neovascular tuft formation. Bars, 200 µm. *, P < 0.05; **, P < 0.005; ***, P < 0.0005; ns, not significant. Data are means ± SD.

This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal